It is widely accepted that thrombophilia in pregnancy greatly increases the risk of venous thromboembolism. Pregnancy complications arise, at least partly, from placental insufficiency. Any change in the functioning of the gestational transient biological system, such as inherited or acquired thrombophilia, might lead to placental insufficiency. In this research we included 64 pregnant women with trombophilia and 70 cases non-trombophilic pregnant women, with or without PMPC, over a two-year period. The purpose of this multicenter case-control study is to analyze the maternal-fetal management options in obstetric thrombophilia, the impact of this pathology on the placental structure and possible correlations with placentamediated pregnancy complications. Maternal-fetal management in obstetric thrombophilia means preconceptional or early diagnosis, prevention of pregnancy morbidity, specific therapy as quickly as possible and fetal systematic surveilance to identify the possible occurrence of placenta-mediated pregnancy complications.
Placenta-mediated pregnancy complications (PMPC) such as preeclampsia, intrauterine growth restriction (IUGR), birth of a small-for gestational age infant, obstetric morbidity and recurrent pregnancy loss, stillbirth or placental abruption, are significant causes of maternal and fetal poor outcome [1] . These complications are believed to result due to thrombophilia, and therefore from thrombosis within the placental angioarchitecture [1] [2] [3] .
The etiology of placenta-mediated pregnancy complications is likely multifactorial and may include abnormal coagulation activation of the maternal-fetal interface [4] .
Normal pregnancy is a state of physiological hypercoagulability involving complex changes in blood fluid-coagulation balance, from primary haemostasis to fibrinolysis and natural anticoagulant mechanisms [5] .
Therefore, any disruption of this balance may interfere with the maternal-fetal interface and cause pregnancy complications.
It is widely accepted that thrombophilia in pregnancy greatly increases the risk of venous thromboembolism [6, 7] . Thus, it is speculated that thrombophilia may compromise the slow low-pressure circulation in the placenta due to micro and macro-vascular thrombosis and possibly abnormal placentation [6] [7] [8] .
Thrombophilia can be inherited or acquired, and the major hereditary forms include deficiency of one of the natural anticoagulant proteins and mutations in genes that * email: claudiamehedintu@yahoo.com; Phone: (+)4 0722312976
All authors have contributed equally to this paper encode coagulation factor V (Leiden mutation, G1691A) or coagulation factor II (mutation G20210A) [1, 5, 9] . The most commonly acquired maternal thrombophilia is the obstetric antiphospholipid syndrome (OAPS) defined as the association of thrombotic events or obstetric morbidity in patients persistently positive for antiphospholipid antibodies (aPL) [1, 10, 11] .
Furthermore, hyperhomocysteinemia, which can be hereditary or acquired, is a risk factor for diseases that primarily affect the arteries [1, 12] .
PMPC could affect over 5% of pregnancies and can result in significant maternal and perinatal morbidity and mortality [13] Duffett et al. in 2015, suggest that these pregnancy complications arise, at least partly, from placental insufficiency, possibly as a result on inappropriate coagulation activation, this pathophysiological association leading to the hypothesis that anticoagulant therapy, such as low molecular weight heparin (LMWH), might reduce their occurence [13] .
LMWH has been proposed as a potential preventive therapy for a number of PMPC including preeclampsia and IUGR [14] .
The use of acetylsalicylic acid (ASA), widely accepted as aspirin, and heparin has improved the pregnancy outcome in OAPS and approximately 70% of pregnant women with this syndrome have a successful pregnancy outcome [11] .
The purpose of this paper is to analyze the maternalfetal management options in obstetric thrombophilia, the impact of this pathology on the placental structure and possible correlations with PMPC.
Experimental part
In this multicenter (see affiliation of the authors) casecontrol study we included 64 pregnant women with trombophilia and 70 cases non-trombophilic pregnant women, with or without PMPC, over a two-year period.
All the patients included in the study were routinely or due to obstetric history, tested for thrombophilia (table 1) .
The first line in the diagnosis of obstetric thrombophilias was represented by the standard screening tests, and then, depending on the results, specific tests followed.
The clinical characteristics of the patients in the study, as well as the tests used according to their profile are presented in table 2.
Ultrasound (US) assessment of all the cases in the study (TG -trombophilia group and nTG --non-trombophilia group) has been performed both via 2D conventional technique and 3D or tomographic US imaging, as well as spectral, color or power Doppler. Obstetrical US assessment included fetal biometry and morphology, as well as placental, umbilical cord and amniotic fluid evaluation, maternal-fetal Doppler profile and in the case of multiple pregnancies, the diagnosis of corionicity and amnionicity.
Placentas from the pregnancies of the study group were sent to the pathology department. The placenta specimens resulting after birth were fixed in 10% buffered neutral formalin, processed by paraffin embedding and Haematoxylin and Eosin staining. The pathological assessment of the specimens, included according to the study protocol, the systemantic analysis for perivillous or subchorionic fibrin depositions, maternal floor infarction/ The research meets the conditions of the ethical guidelines and legal requirements, and was approved by each Ethical Committee of the Universities of Medicine and Pharmacy (see authors' affiliations). Informed consent was obtained from every patient included in the study.
Results and discussions
Of the 64 pregnant women diagnosed with trombophilia included in the study, 51 (79.68%) had inherited trombophilic disorders, 11 (17.18%) acquired disease and 2 (3.12%) cases hyperhomocysteinemia, which might be either hereditary or acquired (table 3) .
Our management in TG cases included maternal-fetal US monitoring starting with the first trimester of pregnancy and the establishment of specific treatment as early as possible. This involved administration of acetylsalicylic acid, folic acid, vitamin B6 and B12 supplements and LMWH (Enoxaparin, Dalteparin, Nadroparin and Tinzaparin) (table 4) .
Regarding the association between thrombophilia and PMPC, on our series we observed a relative increase in the incidence of preeclampsia (32.81% vs. 25.71%) or IUGR (37.5% vs. 24.28%), but also a significant increase of recurrent miscarriages, late pregnancy loss (21.87% vs. 4.28%) or stillbirth and placental abruption, in the group of patients associating this condition (table 5) .
Gestational age at delivery has been relatively lower in cases of thrombophilia compared to non-thrombophilic cases, the same trend being observed in the case of birth weight (table 5) .
Placental pathology analysis revealed rather uncharacteristic aspects between the two groups, with slight increases in incidence of placental infarction and perivillous fibrin deposition, but also more significant increases in the case of intervillous thrombosis (14.06% vs.7.14%) or umbilical cord thrombosis, with regard to the thrombophilia group (table 5, fig. 1-8 ). Other aspects of the umbilical cord pathology observed in our series were Table 3 TYPES OF THROMBOPHILIA AND SPECIFIC MARKERS hypercoiled cord, true cord knot, reduced cord coiling or excessively long cord ( fig. 9, 10 ). The pregnancy itself represents a state of acquired hypercoagulability, with an increase in coagulation factors and a decrease in fibrinolysis activity, state which occurs naturally, and which predisposes to deep vein thrombosis, especially as the venous return slows down, by the pressure of the expanding uterus, favoring stasis [18] .
Placentation involves trophoblast invasion of nearly one hundred spiral arterioles with subsequent remodelling resuliting in a low resistance placental circulatory system without maternal vasomotor control, and hence, the resulting low resistance utero-placental circulatory system allows for high volume blood flow in the placenta ond fetus [13, 19] .
Any change in the functioning of this gestational transient biological system, such as inherited or acquired thrombophilia, might lead to placental insufficiency.
PMPC such as severe preeclampsia, IUGR or still birth are attributed to placental insufficiency [20] .
Placental pathology is thought to arise from placental developmental dysfunction in a two-step sequence, meaning failure of trophoblast invasion, followed by systemic endothelial dysfunction, therefore in PMPC, shallow trophoblast invasion is obvious, resulting in a higher placental vascular resistance, decreased placental perfusion and placental ischemia [13, 21, 22] .
It is also believed that about half of gestational venous thromboembolisms are associated with inherited thrombophilia, and anticoagulant therapy to prevent adverse pregnancy outcomes are increasingly used [23] .
In our series, LMWH (table 4) have been used in 47 (73.43%) of TG cases, the choice of the active substance based on obstetricians' experience, clinical practice, hematological consultation, thus we can assert that the obstetrical outcome is encouraging.
Low-dose acetylsalicylic acid (table 4) , together with LMWH or alone, used preconceptionally, in the first part of pregnancy or even to the end of it, brings benefits in the maternal-fetal outcome in thrombophilia in general, and in OAPS in particular.
Many studies to the date stated that the current standard of treatment in OAPS is mainly relying on antithrombotic and antiaggregation treatment, the combination of lowdose acetylsalicylic acid and LMWH (or heparin) has resulted in a live birth rate of 70-80% [11, [24] [25] [26] .
Furthermore, characterization of biochemical and immunological mechanisms involved in development of PMPC could help to early diagnose, to discover new screening methods, and provide new insights into therapy [27, 28] .
Franco et al. [20] consider that the most common placental lesion is infarction of placental villi, whose frequency correlates with disease severity and antenatal test results of placental function, meaning uterine artery Doppler and placental morphology [20, 29] .
In our series, placental infarction was the most common pathological finding in both TG and nTG. We believe that in thrombophilia cases, associated or not with PMPC, it can be discussed rather by a combination of pathological changes, not by specific findings.
The present study has some potential strengths and limitations. The strengths of the study mean the complex analysis and correlations obtained in thrombophilia associated or not with PMPC, integrating in a multicentre research data on comprehensive thrombophilia screening and testing, therapeutic management, placental morphology and pregnancy outcome. Our study is limited however, by the rather low number of cases included, and this may impact the statistical power of our analysis.
Conclusions
Pregnancy is a state of physiological hypercoagulability involving complex changes in blood fluid-coagulation, therefore any disruption of this balance may interfere with the maternal-fetal interface and cause pregnancy complications. Maternal-fetal management in obstetric thrombophilia comprises preconceptional or early diagnosis during gestation, prevention of pregnancy morbidity and ensuring of specific therapy as quickly as possible. Fetal systematic surveilance should assess the biometric and haemodynamic profile to identify the possible occurrence of PMPC. Our study suggests that PMPC occurs with a relatively higher incidence in thrombophilia than in nontrombophilic cases. In thrombophilia associated or not with PMPC there is rather a combination of placental pathological changes, not specific findings. Fig.9 . Gross appearance of the umbilical cord from a TG pregnancy, demonstrating hypercoiled cord, false knot and thrombosis (arrow) Fig.10 . Gross appearance of the umbilical cord from a nTG pregnancy, demonstrating true cord knot, excessive cord twisting and thrombosis (arrow)
